secwatch.observer — SEC 8-K summary
======================================

Issuer:     TransMedics Group, Inc. (TMDX)
CIK:        0001756262
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0000950170-23-003766
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransMedics Q4 revenue $31.4M (+225% YoY); guides FY2023 $138-145M
------------------------------------------------------------------

- Total revenue $31.4M in Q4 2022, up 225% from $9.7M in Q4 2021; full-year revenue $93.5M (+209%).
- Net loss narrowed to $6.7M in Q4 2022 from $12.7M; full-year net loss $36.2M vs $44.2M in 2021.
- Gross margin 66% in Q4 vs 72% prior year; full-year gross margin flat at 70%.
- Cash and equivalents $201.2M as of Dec 31, 2022; operating expenses rose to $27.5M in Q4.
- FY2023 revenue guidance $138-145M (48-55% growth); appointed Nick Corcoran as SVP Supply Chain in Jan 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1756262/000095017023003766/0000950170-23-003766-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1756262/000095017023003766/tmdx-20230222.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-003766

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer